脂必泰与阿托伐他汀的调脂疗效及对血管内皮功能影响  

Impacts of zhibitai and atorvastatin on therapeutic effect of lipid adjustment and blood vessel endothelium function

作　　者：贾圣英[1] 黄全跃[1] 周祁娜[1] 

机构地区：[1]中南大学湘雅二医院心内科,长沙410011

出　　处：《临床心血管病杂志》2010年第12期909-911,共3页Journal of Clinical Cardiology

摘　　要：目的:观察脂必泰胶囊对心血管高危患者的调脂疗效及其对血管内皮功能的影响。方法:将83例具有2个或2个以上心血管疾病危险因素的患者随机分为2组,分别接受脂必泰及阿托伐他汀治疗,于治疗前和治疗8周观察血脂各成分的变化,并测定肱动脉内皮依赖性舒张功能(FMD)。结果:脂必泰治疗8周可使心血管病高危患者的血清TG、TC、LDL-C水平降低(P<0.05),FMD显著提高(P<0.05),和阿托伐他汀组相比,差异无统计学意义(P>0.05),治疗前后HDL-C水平无明显变化(P>0.05)。结论:脂必泰能有效降低心血管病高危患者的TC、TG、LDL-C水平,与阿托伐他汀相比,降低TC、TG和LDL-C的程度相近。除调脂作用外,脂必泰还能有效改善FMD,从而改善血管内皮功能。Objective：To evaluate the effects of Zhibitai capsule on blood lipids and endothelial function in patients with high cardiovascular risks.Method：Eighty three subjects with high risk factors of cardiovascular disease were randomized into Zhibitai group and atorvastatin group with eight weeks＇ treatment.Flow-mediated dilation （FMD） was measured by Doppler ultrasound technique before and after the treatments.Result：The levels of triglyeride （TG）,total cholesterol （TC） and low density lipoprotein cholesterol （LDL-C） were decreased markedly after therapy with Zhibitai and atorvastatin for 8 weeks （P0.05）,but high density lipoprotein cholesterol （HDL-C） had no significant changes after therapy for 8 weeks in both Zhibitai and atorvastatin group （P0.05）.The variation of the TC,TG and LDL-C levels had no difference between two groups （P0.05）.The levels of flow-mediated dilatation （FMD） were significantly up-regulated in two groups.Conclusion：Zhibitai has the same benefitial effects on reducing blood levels of TG,TC and LDL-C as atorvastatin.Besides,it can increase FMD,thus improving vascular endothelial function.

关 键 词：冠心病 脂必泰 阿托伐他汀 血管内皮功能 肱动脉内皮依赖性舒张功能 

分 类 号：R541.4[医药卫生—心血管疾病]